Pharma Mar S.A (PHM) | Stock Overview & Key Data
Pharma Mar S.A. | Large-cap | Healthcare
Pharma Mar S.A. | Large-cap | Healthcare
Pharma Mar S.A Performance Comparison
Stock Range
Today's Range
Low: €79.05
High: €81.30
on August 4, 2025
52 Week Range
Low: €35.06
High: €105.80
on August 8, 2024
on March 3, 2025
All-Time High: €323.28 on October 2, 2000
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€1.4B
EPS
1.13
P/E Ratio (TTM)
70.13
Forward P/E
21.48
P/B Ratio
6.68
PEG Ratio
21.48
Div. Yield
0.86%
ROE
21.94%
Beta
N/A
Debt to Equity
25.51
Financial Highlights
Profitability
Gross Margin
91.25%
Operating Margin
42.83%
Profit Margin
22.20%
Returns and Earnings
Return on Assets (TTM)
5.91%
Return on Equity (TTM)
21.94%
EBITDA
€21.0M
Net Income (TTM)
€42.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€10.77
Quarterly Revenue Growth (YoY)
31.50%
Quarterly Earnings Growth (YoY)
1,789.20%
Dividend Information
Last 12-Month Dividend
€0.68
Current Dividend Yield
0.86%
3-Year Average Dividend Yield
1.42%
3-Year Average Annual Dividend
€0.88
3-Year Total Dividends
€2.63
Ex-Dividend Date
June 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Pharma Mar S.A PHM | 1.38B Large-cap | -4.11% | -0.06% | 4.90% | -12.96% | -1.00% | 106.70% | 28.61% | -8.80% |
| Atrys Health S.A ATRY | 217.06M Mid-cap | -4.35% | 10.00% | -0.69% | -18.29% | -18.29% | -8.63% | -55.03% | -61.35% |
| Oryzon Genomics S.A ORY | 202.31M Mid-cap | -5.09% | -2.61% | -1.88% | 82.52% | 74.00% | 45.81% | 3.16% | -3.33% |
| Vytrus Biotech S.A VYT | 42.89M Small-cap | 0.00% | 35.71% | 72.73% | 156.76% | 163.89% | 77.57% | 83.87% | 102.13% |
| Biotechnology Assets BST | 23.82M Small-cap | -2.78% | -14.63% | 20.69% | 9.38% | 25.00% | 9.38% | 84.21% | -58.33% |
| Grifols, S.A GRF | 7.85B Large-cap | 5.04% | 24.21% | 51.58% | 58.65% | 36.68% | 45.94% | -8.10% | -47.67% |
Ownership & Short Interest
Insider Ownership
29.37%
Institutional Ownership
8.75%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
57K
Average 90-Day Volume
45K
Pharma Mar S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Pharma Mar S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PHM's 52-week high and low?
- In the last 52 weeks, Pharma Mar S.A reached a high of €105.80 (on March 3, 2025) and a low of €35.06 (on August 8, 2024).
- What is the market cap and P/E ratio for PHM?
- Curious about Pharma Mar S.A's size and valuation? Its market capitalization stands at 1.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is 70.13, and the forward P/E (looking ahead) is 21.48.
- Does PHM pay dividends? If so, what's the yield?
- Yes, Pharma Mar S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.86%, and the company has paid an average of €0.88 per share annually over the past 3 years.
- Who are Pharma Mar S.A's main competitors or similar companies to consider before investing?
When looking at Pharma Mar S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Atrys Health S.A
ATRY217.06M Healthcare Biotechnology -8.63% -55.03% Oryzon Genomics S.A
ORY202.31M Healthcare Biotechnology 45.81% 3.16% Vytrus Biotech S.A
VYT42.89M Healthcare Biotechnology 77.57% 83.87% Biotechnology Assets
BST23.82M Healthcare Biotechnology 9.38% 84.21% Grifols, S.A
GRF7.85B Healthcare Drug Manufacturers - General 45.94% -8.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pharma Mar S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Pharma Mar S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 21.94%, the Debt to Equity ratio from the most recent quarter is 25.51, and its Gross Profit Margin stands at 91.25%.
- What is the recent revenue and earnings growth for PHM?
- Looking at Pharma Mar S.A's growth, its revenue over the trailing twelve months (TTM) was €189M. Compared to the same quarter last year (YoY), quarterly revenue grew by 31.50%, and quarterly earnings saw a YoY growth of 1,789.20%.
- How much of PHM stock is held by insiders and institutions?
- Wondering who owns Pharma Mar S.A stock? Company insiders (like executives and directors) hold about 29.37% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 8.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.